Abstract: An antitumor agent comprising as an active ingredient a DNase, and novel DNases are disclosed. The novel DNases are derived from human stomach cancer cell line MKN-28 or human cervical cancer cell line HeLa, and do not act on normal cells but specifically act on cancer cells.

Abstract: A compound for use especially as an antiviral drug, mainly containing salts of heteropolyanions consisting of a tungstoantimonate (III) vanadium-mixed metal oxide or related salts represented by formula [(XW9O33)2V3O3]P−, where p is a positive number between 9 and 12 and X is Sb, P. As or Bi and especially Sb. An antiviral drug having a broad spectrum of antiviral activity, high potent efficacy and low toxicity is provided.

Abstract: A pharmaceutical composition for treating or preventing influenza comprising an oligonucleotide containing a base sequence complementary to a base sequence of a target region containing a translational initiation codon AUG of a PB2 gene or a PA gene, a liposome stable in blood, and a pharmaceutically acceptable carrier or dilute is disclosed. The pharmaceutical composition for treating or preventing influenza can be used in an effective treatment of or prevention of an infection by influenza viruses.

Abstract: A compound for use especially as an antiviral drug, mainly containing salts of heteropolyanions consisting of a tungstoantimonate (III) vanadium-mixed metal oxide or related salts represented by formula [(XW9O33)2V3O3]p−, where p is a positive number between 9 and 12 and X is Sb, P. As or Bi and especially Sb. An antiviral drug having a broad spectrum of antiviral activity, high potent efficacy and low toxicity is provided.

Abstract: The invention provides 4′-C-ethynyl pyrimidine nucleosides (other than 4′-C-ethynylthymidine) represented by formula [I]: wherein B represents a base selected from the group consisting of pyrimidine and derivatives thereof; X represents a hydrogen atom or a hydroxyl group; and R represents a hydrogen atom or a phosphate residue; and a pharmaceutical composition containing any one of the compounds and a pharmaceutically acceptable carrier. Preferably, the composition is used as an anti-HIV agent or a drug for treating AIDS.

Abstract: The invention provides 4′-C-ethynyl pyrimidine nucleosides (other than 4′-C-ethynylthymidine) represented by formula [I]: 1

Abstract: The invention provides 4′-C-ethynyl pyrimidine nucleosides (other than 4′-C-ethynylthymidine) represented by formula [I]: wherein B represents a base selected from the group consisting of pyrimidine and derivatives thereof; X represents a hydrogen atom or a hydroxyl group; and R represents a hydrogen atom or a phosphate residue; and a pharmaceutical composition containing any one of the compounds and a pharmaceutically acceptable carrier. Preferably, the composition is used as an anti-HIV agent or a drug for treating AIDS.

Abstract: Novel arylthiadiazole derivatives and salts thereof useful for preventing and treating human viral infection and a novel virucide which contains the arylthiadiazole derivative or a salt thereof are provided. N,N-dimethyl ?3-(3-(amino-2,6-dichlorophenyl)-1,2,5-thiadiazol-4-yl! carbamate or its salt, and virucide containing the same as an effective component.

Abstract: Antiviral agents comprising, as an active ingredient, a 1,4-dihydro-2,3-benzodithiin derivative of the formula ##STR1## wherein each symbol is as defined in the Specification, or a pharmacologically acceptable salt thereof. The antiviral agents of the present invention have superior antiviral activity and are effective for the preventive and therapeutic treatment of viral diseases caused typically by RS virus.

Abstract: The present invention relates to human monoclonal antibodies capable of plurally binding with O-antigens of Pseudomonas aeruginosa, relates to novel parent cell lines for producing human hybridomas derived from human immunoglobulin synthesizing cells, which cell lines themselves incapable of producing human immunoglobulin and capable of fusing with human antibody-producing cells, relates to human-human hybridomas which can secrete monoclonal antibodies capable of binding with at least one of serotypes of Pseudomonas aeruginosa, relates to pharmaceutical compositions for prophylaxis or therapy of Pseudomonas aeruginosa infectious diseases, and relates to prophylactic or therapeutic methods for Pseudomonas aeruginosa infectious diseases.

Abstract: PSC-A is a new serological common antigen to Pseudomonas aeruginosa having very low toxicity, and highly effective for protecting infection by any of the serotypes of Pseudomonas aeruginosa. PSC-A can be used as the active component in a pharmaceutical agent for protecting Pseudomonas aeruginosa infection.

Abstract: PSC-A is a new serological common antigen to Pseudomonas aeruginosa having very low toxicity, and highly effective for protecting infection by any of the serotypes of Pseudomonas aeruginosa. PSC-A can be used as the active component in a pharmaceutical agent for protecting Pseudonomas aeruginosa infection.